October 31, 2024 Bio/Pharma/CRO PAI Top-10 Product Launch

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one... Read more

October 29, 2024 Life Science Tools Microscopy

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such... Read more

October 28, 2024 Lab Top-10 Life Science Tools PR/Corporate

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the... Read more

October 23, 2024 Lab Top-10 PAI Top-10 PR/Corporate

Thermo Fisher Scientific Reports Third Quarter 2024 Results

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.25. Third quarter adjusted EPS was $5.28. Advanced... Read more

October 23, 2024 PAI Top-10 PR/Corporate

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

Group sales grew by 6%1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarter... Read more

October 22, 2024 Life Science Tools M&A, Partnerships PAI Top-10

PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program

MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and... Read more

October 22, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher Reports Third Quarter 2024 Results

WASHINGTON, Oct. 22, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per... Read more

October 21, 2024 Lab Top-10 Liq. Handling & Robotics

Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics

Robust, Unbiased and Affordable 4D-Proteomics™ for Highest-Specificity Protein IDs & Quant Enables High-Fidelity Large-Scale Plasma Proteomics Typical Sequence Coverage >10 Peptides/protein and >100k Peptides per Cell-Line Proteome Ushers in HiFi Proteomics with High Isoform Specificity Novel diagonal-PASEF ® methods for immunopeptidomics and PTM characterization Achieving one-hundred-dollar high-fidelity plasma proteomics with PreOmics ENRICH™ and robust timsTOF... Read more

October 17, 2024 Lab Top-10 Licensing, IP, and Legal

European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString’s CosMx SMI Products

BILLERCA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the “928 Patent”), which has been asserted by 10x Genomics against NanoString’s CosMx® Spatial Molecular Imager (SMI) products in Europe. Today’s ruling follows the May 2024... Read more